文献速递泌尿生殖介入MRUS

超声引导经会阴前列腺局灶激光消融后1年随访:全球注册研究

One-year Follow-up after US-guided Transperineal Focal Laser Ablation of Localized Prostate Cancer: Worldwide Registry Study.
PubMed 文献 · Radiology · 2026-01-01

多中心回顾性分析195例局限性前列腺癌患者共206个病灶,行MRI引导下超声引导经会阴局灶激光消融(TPLA)后随访12个月。结果显示临床有意义前列腺癌野内复发(csIFR)率为17%,总体野内复发率为24%。术后MRI阳性对csIFR具有高度预测价值,敏感度83%,特异度89%。

要点

  • 术后MRI阳性(PI-RADS≥3)高度预测csIFR,应作为常规随访手段。
  • 初始PSAD>0.16 ng/mL²是术前独立预测csIFR的因素,可用于筛选适合消融的患者。
  • 12个月csIFR率为17%,总体IFR率为24%,提示TPLA后需规范随访活检。

核心结论

  • MRI引导下超声引导经会阴局灶激光消融治疗206个局限性前列腺癌病灶,12个月csIFR率为17%。
  • 术后MRI阳性结果对csIFR具有高度预测价值,OR为67.87。

研究设计与样本

  • 回顾性注册研究,数据来自欧洲和美国4个中心,时间为2018年5月至2023年7月。
  • 纳入195例活检证实、MRI勾画的PI-RADS≥3病灶患者,共206个病灶行单纤维或多纤维TPLA。
  • TPLA参数为1064 nm波长、3-5 W功率,最小随访12个月,包括PSA、PSAD、MRI及方案化或MRI指示的活检。
  • 参考标准为随访活检病理结果,csIFR定义为治疗区内Gleason评分≥3+4的活检证实前列腺癌。

关键影像表现/征象

  • 随访MRI阳性定义为PI-RADS≥3病灶,术后MRI阳性预测csIFR的敏感度83%,特异度89%。
  • 病灶Gleason评分分布:32%为3+3,48%为3+4,29%为4+3,7%为4+4。
  • 中位初始PSA为6.8 ng/mL,中位肿瘤长度为11 mm。

诊断标准与关键数值

  • csIFR定义为治疗区域内穿刺证实Gleason评分≥3+4的前列腺癌,总体IFR定义为治疗区域内任何级别前列腺癌。

临床应用与阅片要点

  • 随访中应将MRI作为核心评价手段,PI-RADS≥3病灶需高度警惕csIFR并行活检确认。
  • 初始PSAD>0.16 ng/mL²的患者消融后复发风险较高,随访中应加强监测。
  • 报告TPLA后MRI时应重点评价治疗区有无PI-RADS≥3残留或新生强化病灶。

局限性

  • 回顾性研究设计,存在选择偏倚可能。
  • 多中心数据但设备与操作细节可能存在异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Despite growing research interest in focal therapies for localized prostate cancer (PCa) tumors, no large cohort studies have evaluated the oncological outcomes of US-guided transperineal focal laser ablation (TPLA). Purpose To evaluate the 12-month oncological outcomes of MRI-directed US-guided TPLA in patients with localized PCa. Materials and Methods Patient data from four centers in Europe and the United States (May 2018 to July 2023) were retrospectively analyzed. Single-fiber or multifiber TPLA was performed (1064 nm, 3-5 W) for biopsy-confirmed, MRI-delineated Prostate Imaging Reporting and Data System (PI-RADS) 3 or higher lesions. The minimum follow-up was 12 months and included prostate-specific antigen (PSA) and PSA density (PSAD) measurements, MRI, and protocolized or MRI-indicated biopsy. MRI positivity was defined as a PI-RADS 3 or higher lesion at follow-up imaging. In-field recurrence (IFR) was defined as biopsy-proven PCa within the treated area; the IFR of clinically significant PCa (csIFR) was defined as a Gleason score (GS) of at least 3+4. Predictors of csIFR were assessed at three predefined stages (preoperative, perioperative, and postoperative). Stage-specific mixed-effects multivariable analyses were conducted with variables that were statistically significant in univariable analysis after accounting for known predictors. Results Overall, 195 men (median age, 69 years; IQR, 63-74 years) underwent TPLA for 206 lesions, of which 32% were GS 3+3, 48% were GS 3+4, 29% were GS 4+3, and 7% were GS 4+4. The median initial PSA level was 6.8 ng/mL (IQR, 5.4-9.0 ng/mL), and the median tumor length was 11 mm (IQR, 9-14 mm). csIFR was detected in 36 of the 206 (17%) lesions, with an overall IFR rate of 49 of 206 (24%). An initial PSAD greater than 0.16 ng/mL2 was an independent preoperative predictor of csIFR (odds ratio [OR]: 2.62; 95% CI: 1.01, 6.89; P = .049). Postoperatively, positive MRI findings were predictive of csIFR (OR: 67.87; 95% CI: 18.74, 246.01; P < .001), with 83% sensitivity and 89% specificity. Conclusion In this multicenter study, MRI-directed, US-guided TPLA of 206 localized PCa lesions resulted in a 12-month csIFR rate of 17%. Post-TPLA positive MRI findings were highly predictive for csIFR. ClinicalTrials.gov identifier: NCT05163197 © RSNA, 2026 Supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. de Bie, Cornud, Walser, et al. One-year Follow-up after US-guided Transperineal Focal Laser Ablation of Localized Prostate Cancer: Worldwide Registry Study. Radiology. 2026. PMID: 42227864. doi:10.1148/radiol.251658

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。